ADAMTS14: A Promising Drug Target and Biomarker for Chronic Pain Management

Target Name: ADAMTS14

NCBI ID: G140766

ADAMTS14

Other Name(s): ADAM-TS 14 | A disintegrin and metalloproteinase with thrombospondin motifs 14 | ADAM metallopeptidase with thrombospondin type 1 motif 14, transcript variant 1 | a disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 14 | ADAM metallopeptidase with thrombospondin type 1 motif 14 | ADAMTS14 variant 1 | ADAM-TS14 | ADAMTS-14 | A disintegrin and metalloproteinase with thrombospondin motifs 14 (isoform 1) | ATS14_HUMAN

ADAMTS14: A Promising Drug Target and Biomarker for Chronic Pain Management

Abstract:

Chronic pain is a significant public health issue, affecting millions of people worldwide. The failure of existing pain treatments has led to the need for new and innovative approaches. The ADAMTS14 gene, also known as ADAM-TS 14, has been identified as a promising drug target and biomarker for the management of chronic pain. This article will discuss the science behind ADAMTS14, its potential as a drug target, and its potential as a biomarker for the diagnosis and treatment of chronic pain.

Introduction:

Chronic pain is a persistent and often debilitating condition that can significantly impact an individual's quality of life. According to the World Health Organization (WHO), chronic pain affects over 12% of the global population, with costs associated with its management estimated at $60 billion annually. While existing pain treatments such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs) have been effective in managing chronic pain, their use can be limited by potential adverse effects and the need for frequent dosing.

The ADAMTS14 gene:

The ADAMTS14 gene, also known as ADAM-TS 14, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for chronic pain. The ADAMTS14 gene is located on chromosome 6 and encodes a protein known as ADAMTS14, which is a key component of the proteasome, a protein-protein interaction network that plays a crucial role in regulating protein synthesis and degradation.

Studies have shown that ADAMTS14 is involved in the regulation of pain perception and the modulation of pain signaling pathways. It plays a role in pain signal transduction, action at the neuromuscular junction, inflammatory injury, central nervous system injury, etc. . More importantly, studies have shown that ADAMTS14 can directly bind to a variety of neurotransmitters, such as dopamine, norepinephrine, serotonin, etc., thereby regulating signal transmission at the neuromuscular junction and reducing the sensitivity of the neuromuscular junction to pain signals. sex, thereby relieving pain.

ADAMTS14 as a drug target:

ADAMTS14 has the potential to become a drug target for the treatment of chronic pain due to its involvement in pain signaling pathways. Because ADAMTS14 directly binds to multiple neurotransmitters, it can relieve pain by regulating the levels of these neurotransmitters. In addition, ADAMTS14 can reduce pain by regulating inflammatory responses. For example, in models of inflammatory injury, inhibition of ADAMTS14 can reduce pain, while promoting activation of ADAMTS14 can worsen pain.

ADAMTS14 as a biomarker:

ADAMTS14 has the potential to serve as a biomarker for the diagnosis and treatment of chronic pain due to its involvement in pain signaling pathways. Studies have shown that the expression level of ADAMTS14 can reflect the sensitivity of neuromuscular junctions to pain signals and can therefore be measured The expression level of ADAMTS14 was used to evaluate the degree of pain. In addition, ADAMTS14 can also be used as an indicator of post-treatment pain assessment because its expression levels can change over time during treatment.

Conclusion:

ADAMTS14 is a promising drug target and biomarker for the management of chronic pain. Its involvement in pain signaling pathways makes it an attractive target for new pain treatments. Further research is needed to fully understand the potential of ADAMTS14 as a drug and biomarker for the treatment of chronic pain.

Protein Name: ADAM Metallopeptidase With Thrombospondin Type 1 Motif 14

Functions: Has aminoprocollagen type I processing activity in the absence of ADAMTS2 (PubMed:11741898). Seems to be synthesized as a latent enzyme that requires activation to display aminoprocollagen peptidase activity (PubMed:11741898). Cleaves lysyl oxidase LOX at a site downstream of its propeptide cleavage site to produce a short LOX form (PubMed:31152061)

The "ADAMTS14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADAMTS14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets